Clene presents RESTORE-ALS Phase 3 trial design for CNM-Au8 at NEALS meeting

Clene Inc.

Presented preliminary design for RESTORE-ALS, an international Phase 3 trial of CNM-Au8 30 mg for ALS.
Presentation made at the 2024 Annual NEALS Meeting on October 23, 2024.
No efficacy or safety results disclosed; only the trial design was shared.

item 7.01 item 9.01

Clene Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-031805

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.